196 related articles for article (PubMed ID: 38003982)
21. Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies.
Su S; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y; Wang X; Li T; Li J; Chen M; Lu Y; Bai Y; He Z; Lu B
BMC Cancer; 2016 Nov; 16(1):908. PubMed ID: 27871270
[TBL] [Abstract][Full Text] [Related]
22. Role of immunotherapy in oligometastatic nonsmall cell lung cancer.
Galili Y; El-Far A; Tseng J; Carlan S
BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 33972298
[TBL] [Abstract][Full Text] [Related]
23. Management of non-small cell lung cancer with oligometastasis.
Villaruz LC; Kubicek GJ; Socinski MA
Curr Oncol Rep; 2012 Aug; 14(4):333-41. PubMed ID: 22535505
[TBL] [Abstract][Full Text] [Related]
24. [Current Treatment Status and Prospect of Surgery and Thermal Ablation for
Pulmonary Oligometastases in Non-small Cell Lung Cancer].
Liu B
Zhongguo Fei Ai Za Zhi; 2023 Mar; 26(3):238-244. PubMed ID: 37035886
[TBL] [Abstract][Full Text] [Related]
25. Evolution of treatment strategies for oligometastatic NSCLC patients - A systematic review of the literature.
Schanne DH; Heitmann J; Guckenberger M; Andratschke NHJ
Cancer Treat Rev; 2019 Nov; 80():101892. PubMed ID: 31522079
[TBL] [Abstract][Full Text] [Related]
26. The "new" oligometastatic disease state and associated therapies in non-small cell lung cancer: A narrative review.
Na KJ; Kim YT
J Surg Oncol; 2023 Feb; 127(2):282-287. PubMed ID: 36464990
[TBL] [Abstract][Full Text] [Related]
27. Oligometastasis: Past, Present, Future.
Gutiontov SI; Pitroda SP; Weichselbaum RR
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):530-538. PubMed ID: 32976785
[TBL] [Abstract][Full Text] [Related]
28. Oligometastasis and oligo-recurrence: more than a mirage.
Huang F; Wu G; Yang K
Radiat Oncol; 2014 Oct; 9():230. PubMed ID: 25359216
[TBL] [Abstract][Full Text] [Related]
29. Oligometastatic status as predictor of survival in metastatic human papillomavirus-positive oropharyngeal carcinoma.
Albergotti WG; Abberbock S; Mathews F; Ferris RL; Johnson JT; Duvvuri U; Kim S
Head Neck; 2018 Aug; 40(8):1685-1690. PubMed ID: 29756301
[TBL] [Abstract][Full Text] [Related]
30. Oligometastatic Head and Neck Cancer: Challenges and Perspectives.
Bahig H; Huang SH; O'Sullivan B
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010888
[TBL] [Abstract][Full Text] [Related]
31. A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC).
Panje CM; Dedes KJ; Matter-Walstra K; Schwenkglenks M; Gautschi O; Siano M; Aebersold DM; Plasswilm L; Lupatsch JE;
Radiother Oncol; 2018 Nov; 129(2):257-263. PubMed ID: 30104008
[TBL] [Abstract][Full Text] [Related]
32. The emerging role of local therapy in oligometastatic non-small cell lung cancer.
Isbell JM; Li BT; Gomez DR
J Thorac Cardiovasc Surg; 2022 Mar; 163(3):819-825. PubMed ID: 34147255
[No Abstract] [Full Text] [Related]
33. Stereotactic radiotherapy in oligometastatic cancer.
Kennedy TAC; Corkum MT; Louie AV
Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S16. PubMed ID: 28917254
[TBL] [Abstract][Full Text] [Related]
34. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer.
Parikh RB; Cronin AM; Kozono DE; Oxnard GR; Mak RH; Jackman DM; Lo PC; Baldini EH; Johnson BE; Chen AB
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):880-7. PubMed ID: 24867533
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors of oligometastatic non-small-cell lung cancer following radical therapy: a multicentre analysis.
Opitz I; Patella M; Payrard L; Perentes JY; Inderbitzi R; Gelpke H; Schulte S; Diezi M; Gonzalez M; Krueger T; Weder W
Eur J Cardiothorac Surg; 2020 Jun; 57(6):1166-1172. PubMed ID: 32011665
[TBL] [Abstract][Full Text] [Related]
37. The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope.
Bansal P; Rusthoven C; Boumber Y; Gan GN
Future Oncol; 2016 Dec; 12(23):2713-2727. PubMed ID: 27467543
[TBL] [Abstract][Full Text] [Related]
38. Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC.
Gauvin C; Krishnan V; Kaci I; Tran-Thanh D; Bédard K; Albadine R; Leduc C; Gaboury L; Blais N; Tehfe M; Routy B; Florescu M
Curr Oncol; 2021 Jan; 28(1):593-605. PubMed ID: 33498159
[TBL] [Abstract][Full Text] [Related]
39. Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy.
Saisho S; Yasuda K; Maeda A; Yukawa T; Okita R; Hirami Y; Shimizu K; Nakata M
Interact Cardiovasc Thorac Surg; 2013 Feb; 16(2):166-72. PubMed ID: 23143203
[TBL] [Abstract][Full Text] [Related]
40. Advances in Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Targeted Therapy.
Giustini NP; Jeong AR; Buturla J; Bazhenova L
Clin Chest Med; 2020 Jun; 41(2):223-235. PubMed ID: 32402358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
